A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Link
http://www.nature.com/articles/bmt2010239.pdf
Reference17 articles.
1. Comenzo RL . How I treat amyloidosis. Blood 2009; 114: 3147–3157.
2. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85–93.
3. Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004; 104: 1888–1893.
4. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005; 79: 319–328.
5. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B et al. Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a ‘melphalan recall’ reaction. Bone Marrow Transplant 2010; 45: 21–24.
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of Autologous Stem Cell Transplantation in Systemic Light Chain Amyloidosis;Clinical Lymphoma Myeloma and Leukemia;2024-07
2. Systemic Light Chain Amyloidosis;New England Journal of Medicine;2024-06-27
3. Individualized Approach to Management of Light Chain Amyloidosis;Journal of the National Comprehensive Cancer Network;2023-01
4. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients;Bone Marrow Transplantation;2021-11-20
5. Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis;Transplantation and Cellular Therapy;2021-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3